2 results
Approved WMOWill not start
The primary objective of this study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.Secondary objectives include evaluation of the safety and effect of ambrisentan on development of…
Approved WMORecruiting
Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or persistent disease and Cohort 2 - LN-145 monotherapy in patients previously treated with an antiprogrammedcell death…